Drug Profile
Prostate cancer therapeutic vaccine - Vakzine Project Management
Alternative Names: LNCaP/IL-2/IFNγ; VPM 4001Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Vakzine Projekt Management
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer